Literature DB >> 23658027

Perturbations of RNA helicases in cancer.

Francis Robert1, Jerry Pelletier.   

Abstract

Helicases are implicated in most stages of the gene expression pathway, ranging from DNA replication, RNA transcription, splicing, RNA transport, ribosome biogenesis, mRNA translation, RNA storage and decay. These enzymes utilize energy derived from nucleotide triphosphate hydrolysis to remodel ribonucleoprotein complexes, RNA, or DNA and in this manner affect the information content or output of RNA. Several RNA helicases have been implicated in the oncogenic process--either through altered expression levels, mutations, or due to their role in pathways required for tumor initiation, progression, maintenance, or chemosensitivity. The purpose of this review is to highlight those RNA helicases for which there is significant evidence implicating them in cancer biology.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23658027     DOI: 10.1002/wrna.1163

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  18 in total

1.  DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.

Authors:  Yadong Xu; Qiong Song; Laura E Pascal; Mingming Zhong; Yibin Zhou; Jianhua Zhou; Fang-Ming Deng; Jiaoti Huang; Zhou Wang
Journal:  Prostate       Date:  2019-02-03       Impact factor: 4.104

Review 2.  The DEAD-box protein family of RNA helicases: sentinels for a myriad of cellular functions with emerging roles in tumorigenesis.

Authors:  Mohamed A M Ali
Journal:  Int J Clin Oncol       Date:  2021-03-03       Impact factor: 3.402

3.  DHX32 expression is an indicator of poor breast cancer prognosis.

Authors:  Meng Wang; Guojun Zhang; Yajie Wang; Ruimin Ma; Limin Zhang; Hong Lv; Fang Fang; Xixiong Kang
Journal:  Oncol Lett       Date:  2016-12-14       Impact factor: 2.967

Review 4.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  The Q Motif Is Involved in DNA Binding but Not ATP Binding in ChlR1 Helicase.

Authors:  Hao Ding; Manhong Guo; Venkatasubramanian Vidhyasagar; Tanu Talwar; Yuliang Wu
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

6.  Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.

Authors:  Suratno Lulut Ratnoglik; Da-Peng Jiang; Chie Aoki; Pratiwi Sudarmono; Ikuo Shoji; Lin Deng; Hak Hotta
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

7.  Overexpression of DHX32 contributes to the growth and metastasis of colorectal cancer.

Authors:  Huayue Lin; Wenjuan Liu; Zanxi Fang; Xianming Liang; Juan Li; Yongying Bai; Lingqing Lin; Hanyu You; Yihua Pei; Fen Wang; Zhong-Ying Zhang
Journal:  Sci Rep       Date:  2015-03-18       Impact factor: 4.379

Review 8.  What Is the Impact of mRNA 5' TL Heterogeneity on Translational Start Site Selection and the Mammalian Cellular Phenotype?

Authors:  Joseph A Curran; Benjamin Weiss
Journal:  Front Genet       Date:  2016-08-31       Impact factor: 4.599

9.  DDX17 is involved in DNA damage repair and modifies FUS toxicity in an RGG-domain dependent manner.

Authors:  Tyler R Fortuna; Sukhleen Kour; Eric N Anderson; Caroline Ward; Dhivyaa Rajasundaram; Christopher J Donnelly; Andreas Hermann; Hala Wyne; Frank Shewmaker; Udai Bhan Pandey
Journal:  Acta Neuropathol       Date:  2021-06-01       Impact factor: 17.088

10.  The effect of heterogeneous Transcription Start Sites (TSS) on the translatome: implications for the mammalian cellular phenotype.

Authors:  Francois-Xavier Dieudonné; Patrick B F O'Connor; Pascale Gubler-Jaquier; Haleh Yasrebi; Beatrice Conne; Sergey Nikolaev; Stylianos Antonarakis; Pavel V Baranov; Joseph Curran
Journal:  BMC Genomics       Date:  2015-11-21       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.